#736
|
|||
|
|||
Öèòàòà:
__________________
Ñ óâàæåíèåì |
#737
|
||||
|
||||
Óâàæàåìûå êîëëåãè.  íà÷àëå ôåâðàëÿ íà áàçå ÐÊ ÍÏÊ ñîñòîÿëñÿ ñàììèò ïî ãèáðèäíûì ïîäõîäàì ê ëå÷åíèþ ïàòîëîãèè àîðòû, êëàïàííûõ ïîðîêîâ è ÌÔÀ.
Ê ñîæàëåíèþ, ñàì ÿ òàì íå ïðèñóòñòâîâàë. Îäíàêî ïîëíàÿ ïðîãðàììà êîíôåðåíöèè âûëîæåíà â ñâîáîäíîì äîñòóïå è ïðåäñòàâëÿåò äîâîëüíî èíòåðåñíûé ìàòåðèàë. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] - òðàíñëÿöèÿ 1 ôåâðàëÿ [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] - òðàíñëÿöèÿ 2 ôåâðàëÿ |
#738
|
|||
|
|||
À ÿ äàâíî îá ýòîì ãîâîðèëà. Îäíà èç ïðè÷èí ïëà÷åâíûõ ðåçóëüòàòîâ HERS è WHO ñâÿçàíà ñ ïðèìåíåíèå êîíñêîãî êîíúþãèðîâàííîãî ýñòðîãåíà
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Öèòàòà:
__________________
Ñ óâàæåíèåì |
#739
|
||||
|
||||
Statin-Taking Patients With LDL-C of 70–100 mg/dL at Decreased Risk of MACE
Öèòàòà:
|
#740
|
|||
|
|||
Comparison of ACC/AHA and ESC Guideline Recommendations Following Trial Evidence for Statin Usein Primary Prevention of Cardiovascular Disease
Results From the Population-Based Rotterdam Study Öèòàòà:
__________________
Ñ óâàæåíèåì |
#741
|
|||
|
|||
Âûøëè íîâûå [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] ×ÀÂÎ ïî äèñëèïèäåìèè îáíîâëåíî ñîîòâåñòâåííî.
__________________
Ñ óâàæåíèåì |
#742
|
||||
|
||||
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#743
|
||||
|
||||
Marijuana Use Can Double Risk of Takotsubo Cardiomyopathy
Öèòàòà:
Öèòàòà:
References: Singh A, Agrawal S, Fegley M, et al. Marijuana (cannabis) use is an independent predictor of stress cardiomyopathy in younger men.. American Heart Association 2016 Scientific Sessions; November 13, 2016; New Orleans, LA. Abstract S4054 |
#744
|
||||
|
||||
÷òî áóäåò, åñëè äîçó íîâûõ àíòèêîàãóëÿíòîâ ñëåãêà ïåðåäîçîðîâàòü èëè íåäîäîçèðîâàòü ïðè ÔÏ? - ïîâûøàåòñÿ ñìåðòíîñòü íà 90% â ïåðâîì è ðèñê ãîñïèòàëèçàöèé íà 25% âî âòîðîì ñëó÷àå, ïîäðîáíåå
J Am Coll Cardiol. 2016 Dec 20;68(24):2597-2604. Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry. Steinberg BA è ñîàâò. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#745
|
|||
|
|||
The Medical Letter® on Drugs and Therapeutics
December 5, 2016 In Brief PPIs and Torsades de Pointes The Arizona Center for Education and Research on Therapeutics (AZCERT) has recently added the proton pump inhibitors (PPIs) omeprazole (Prilosec, and others), esomeprazole (Nexium, and others), lansoprazole (Prevacid, and others), and pantoprazole (Protonix, and generics) to its lists of Drugs with Conditional Risk of Torsades de Pointes (TdP) and Drugs to Avoid in Patients with Congenital Long QT Syndrome. PPIs do not directly cause prolongation of the QT interval, but they have been associated with hypomagnesemia, which is often accompanied by hypocalcemia and hypokalemia and can result in cardiac repolarization disturbances such as QT interval prolongation. Reports have described cases of QT interval prolongation and TdP associated with severe PPI-induced hypomagnesemia. TdP has also been reported in patients taking a PPI concomitantly with drugs that directly prolong the QT interval. The newer PPIs dexlansoprazole (Dexilant) and rabeprazole (Aciphex, and generics) have not been linked to QT interval prolongation or TdP to date, but they can cause hypomagnesemia. Serum magnesium levels should be monitored periodically in patients taking a PPI for an extended period of time (>2 weeks). If possible, extended PPI therapy should be avoided in patients who require treatment with drugs that carry a known risk of TdP and in those with long QT syndrome. If extended PPI therapy must be used with a drug that prolongs the QT interval, close monitoring of magnesium levels and the QT interval is recommended. |
#746
|
|||
|
|||
Íîâîå ACC/AHA/HRS îôèöèàëüíîå ðóêîâîäñòâî ïî ñèíêîïå.
2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Ñëàéä ðóêîâîäñòâà [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#747
|
|||
|
|||
2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
Êðàòêèé îáçîð [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Â ôîðìàòå PDF [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#748
|
|||
|
|||
Îïóáëèêîâàíà âòîðàÿ ÷àñòü öåëåíàïðàâëåííîãî îáíîâëåíèÿ ðóêîâîäñòâà ïî ñåðäå÷íîé íåäîñòàòî÷íîñòè
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#749
|
||||
|
||||
Öèòàòà:
In patients with NYHA class II and III HF and iron deficiency (ferritin <100 ng/mL or 100 to 300 ng/mL if transferrin saturation is <20%), intravenous iron replacement might be reasonable to improve functional status and QoL. Ïðàâäà ãðàäàöèÿ IIb, íî äîêàçàííîñòü B-R. À âîò ýðèòðîïîýòèíîì ïðè ÕÑÍ ëó÷øå íå áàëîâàòüñÿ: In patients with HF and anemia, erythropoietinstimulating agents should not be used to improve morbidity and mortality
__________________
Àëåêñàíäð Èâàíîâè÷ ñ ïîæåëàíèÿìè êðåïêîãî çäîðîâüÿ |
#750
|
||||
|
||||
åòà öèôðà ñ ó÷åòîì êîððåêöèè íà õð. âîñïàëåíèå è ïîâûøåííûé ñ-ðåàêòèâíûé áåëîê ó áîëüøèíñòâà òàêèõ ïàöèåíòîâ, ïîåòîìó è æåëåçî âíóòðü ó íèõ íåäàâíî íå îêàçàëîñü òàêèì åôôåêòèâíûì êàê â/â:
JAMA. 2017 May 16;317(19):1958-1966. Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |